

GOP-1.1.2-07/1-2008-0007
Multidisciplinary research and development
by DEAK KKK
Red Biotechnology division

■ Clinical investigation of the supplementary effects of R47-PROTUMOL[®] ointment in the treatment of basal cell carcinomas and actinic keratoses before surgical excision or photodynamic therapy

Date: 2011-08-31



DEAK Kooperációs Kutatási Nonprofit Zrt.
6720 Szeged, Dugonics tér 13. • Tel: 62/546-711 • www.deakszeged.hu

Nemzeti Fejlesztési Ügynökség
www.ujszechenyiterv.gov.hu
06 40 638 638



A projekt az Európai Unió támogatásával, az Európai Regionális Fejlesztési Alap társfinanszírozásával valósul meg.

The clinical trials were financed by the Hungarian State

Extract from the clinical trial performed at the Medical University of Szeged:

- While using the R47-PROTUMOL[®] cream several degrees of clinical improvement were experienced among the test subjects.
- The cream significantly reduced the rate of ulceration
- No toxic side effect, no allergic-, irritative reaction occurred while using the R47-PROTUMOL[®] cream
- No progression (growth) was noted in the condition of the tumors during the treatment.

Basal Cell Carcinoma (BCC)



Before treatment



4 weeks after treatment



Before treatment



1 week after treatment



Before treatment



4 weeks after treatment



Before treatment



3 weeks after treatment

Actinic Keratosis (AK)



Before treatment



2 weeks after treatment



3 weeks after treatment



Before treatment



2 weeks after treatment



**THE R47-PROTUMOL[®] TREATMENT CREAM WAS DEVELOPED BY
PROPHARMATECH[®] LTD. EXCLUSIVELY AUTHORIZED FOR ITS
PRODUCTION AND MARKETING.
ALL RIGHTS RESERVED!**
